Suppliers / Stallion Laboratories

Stallion Laboratories

India 2 duplicate records merged Updated 9 July 2026

Stallion Laboratories is a finished-dose manufacturer based in India. It appears in 244 regulatory filings across 10 regulators, without an active US DMF or CEP on file. Its filings concentrate with NAFDAC (NG), ARCSA (EC) and FDA (GH). Its GMP standing is certified by CDSCO (India), UZPHARM (UZ) and NAFDAC (NG), among 6 authorities. Its most recent recorded inspection, by US FDA, closed on 12 July 2024 as VAI. Customs aggregates show $26.1M of exports covering 1,774 molecules to 53 destinations in 2025.

0
active US DMFs
0
valid CEPs
10
registered plants 1 with an FDA FEI number
244
filings across 10 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 12 July 2024 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Ahmedabad, India 3013353854
phase ivvatvaahmedabad 382 445ahmedabad, India Not on file
changodar 382 213ahmedabad, India Not on file
ahmedabad 380 008, India Not on file
vapivapi 396 195valsad, India Not on file
wadhwancit ysurendranagar, India Not on file

4 further sites are on record.

Filings and GMP by regulator

Regulator Filings GMP certificates
NAFDAC (NG) 175 1
ARCSA (EC) 24 None
FDA (GH) 21 1
DIGEMAPS (DO) 6 None
MINSA (CR) 5 None
UZPHARM (UZ) 5 2
CDSCO (India) None 10
US FDA None 1
TMDA (TZ) None 1

Scale

Year Revenue Exports Destinations
2026 YTD Not reported $5.0M 23
2025 Not reported $26.1M 53
2024 Not reported $24.2M 58
2023 Not reported $24.5M 48

Export figures are customs aggregates. We do not publish the identity of any buyer.

Comparing suppliers?

Choose your molecules and target markets. Stallion Laboratories comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 12 July 2024.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates
Customs aggregates
Export values, molecule and destination counts